COMP <GO>
PTCT vs DNTH // ENTERPRISE SCALE & MARKET CAP
PTC Therapeutics Inc. (NASDAQ) VS. Dianthus Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: PTCT 9
— DNTH 2
▲ ENTERPRISE SCALE & MARKET CAP LEADER: PTCT
LAST: $60.88 (+1.52%) • MKT CAP: $5.01B
market-cap
$5.01B
LAST: $82.25 (-0.16%) • MKT CAP: $4.61B
market-cap
$4.61B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PTCT VS. DNTH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PTCT | DNTH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | -30.70% | +115.70 | PTCT | /roic <GO> |
| EV/EBITDA & P/E Valuation | 6.5x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 13.05% | -2.79% | +15.84 | PTCT | /fcf-yield <GO> |
| Operating Margin | 50.10% | -60.00% | +110.10 | PTCT | /operating-margins <GO> |
| Net Profit Margin | 39.50% | -60.00% | +99.50 | PTCT | /net-margins <GO> |
| Revenue Growth (YoY) | 114.50% | -65.00% | +179.50 | PTCT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.73 | 26.00 | -24.27 | DNTH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 4/9 | +5.00 | PTCT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.2 | 46.8 | -3.60 | DNTH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 1.08 | +0.07 | PTCT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 6.6x | 20.0x | -13.40 | PTCT | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $5.01B | $4.61B | $402.3M | PTCT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PTCT REV | DNTH REV | PTCT GROSS % | DNTH GROSS % | PTCT FCF | DNTH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.73B | $2.0M | — | — | $702.3M | -$129.2M |
| FY 2024 | $806.8M | $6.2M | — | — | -$114.2M | -$78.5M |
| FY 2023 | $937.8M | $2.8M | — | — | -$200.6M | -$37.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PTCT // BETA 1.15
DNTH // BETA 1.08